Is Corona Remedies’ IPO an attractive bet for long-term wealth creation?

ET Intelligence Group: Corona Remedies, a pharmaceutical company, plans to raise Rs 655.4 crore through an offer for sale. The promoter group’s stake will drop from 72.5% to 69% after the IPO. The company focuses on the specialist doctors, which is driving revenue growth faster than the Indian pharmaceutical market (IPM). Specialists accounted for 75.8% […]

Trent will likely bounce back in 2026; new labor laws to increase costs, not revenues, says Saurabh Mukherjea

Retail giant Trent’s 40-45% correction is not a valuation mystery; it is the result of a meaningful slowdown in same-store sales (SSG) growth, says Saurabh Mukherjea, founder of Marcellus Investment Managers. Speaking to ET Now, Mukherjea said the decline is reflective of the broader consumption slowdown in India, but policy support offers hope for 2026. […]